Learning Objectives:

  1. At the conclusion of this activity, participants will be able to Learn about the history and challenges of malaria vaccine development
  2. At the conclusion of this activity, participants will be able to Describe the RTS,S/AS01 (Mosquirix) efficacy, safety, and feasibility based on the Phase III trial and the implementation pilot
  3. At the conclusion of this activity, participants will be able to Identify next steps for RTS,S/AS01 and future malaria vaccines
Session date: 
01/10/2022 - 12:00pm to 1:00pm CST
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Nelli Westercamp, PhD